MedTrace Logo

Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

NCT03313778 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2026-03-04

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.

Conditions

Interventions

BIOLOGICAL

mRNA-4157

IM injection

BIOLOGICAL

Pembrolizumab

Intravenous infusion

BIOLOGICAL

SoC Treatment

Intravenous infusion

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-14
Primary Completion
2027-11-21
Completion
2027-11-21
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Japan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03313778 on ClinicalTrials.gov